InterMune Inc.: Industry Research Report

InterMune Inc.

Published Date: October 2009

Published By: SGA Lists

Page Count: 2

Order Code: R406-18053

Questions About This Report

E-mail a Colleague

Printable Page

Fax Your Order

Description

Table of Contents

Similar
Products

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program.

Similar Products

• Algae For Fuel, Algal Oil, Biofuels, Biodiesel, Ethanol And The Future Of Petroleum And Green Energy

Published Nov 2009 by Amadee & Company

• Biotechnology (Pharmaceuticals) Report

Published Nov 2009 by Plimsoll Publishing Ltd.

• Opportunities in Human Embryonic Stem Cell (hESC) Products

Published Nov 2009 by BioInformant Worldwide, L.L.C.

• Global Stem Cell and Advanced Technologies Market

Published Nov 2009 by MarketsandMarkets

• Protein Kinase Therapeutics in Oncology - Where to Commercialize?

Published Oct 2009 by BioSeeker Group AB

• Acorda Therapeutics, Inc. - SWOT Analysis